triazoles has been researched along with ew-7197 in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 8 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, CH; Kim, DK; Krishnaiah, M; Lee, HJ; Lee, K; Park, HJ; Park, SJ; Rao, KS; Sheen, YY; Sreenu, D; Subrahmanyam, VB | 1 |
| Kim, DK; Kim, MJ; Kim, SJ; Kim, SW; Lee, SJ; Nam, JS; Park, SA; Park, SY; Sheen, YY; Son, JY | 1 |
| Kim, DK; Kim, JS; Kim, MJ; Lee, SJ; Nam, JS; Park, SA; Park, SY; Sheen, YY; Woo, HA | 1 |
| Kim, JS; Kim, MJ; Lim, W; Nam, JS; Park, SA; Park, SY; Yhong Sheen, Y | 1 |
| Bae, E; Gu, YK; Hirao, A; Ishihara, K; Jeong, ES; Jin, CH; Jomen, Y; Kim, DH; Kim, DK; Kim, DW; Kim, SJ; Krause, DS; Li, S; Naka, K; Ooshima, A; Oshima, H; Oshima, M; Sheen, YY; Takihara, Y | 1 |
| Kim, CH; Kim, DK; Kim, JS; Kim, MJ; Nam, JS; Park, SA; Park, SY; Sheen, YY | 1 |
| Jun, EJ; Kim, DK; Kim, KY; Kim, MT; Lim, YJ; Park, JH; Song, HY; Tsauo, J; Yang, SG; Yoon, SH | 1 |
| Bae, H; Cho, SW; Do, HS; Han, J; Han, YM; Heo, HJ; Hong, SP; Im, I; Kim, I; Kim, KH; Kim, SJ; Ko, TH; Koh, BI; Koh, GY; Lee, S; Park, JH; Park, JS; Song, S; Youm, JB | 1 |
| Gang, SG; Han, K; Kim, DH; Kim, DK; Kim, KY; Kim, MT; Lee, DH; Park, JH; Song, HY; Tsauo, J; Yang, SG | 1 |
| Choi, EY; Kim, DK; Kim, KY; Kim, MT; Lim, YJ; Park, JH; Song, HY; Tsauo, J; Yoon, SH | 1 |
| Asgharzadeh, F; Avan, A; Binabaj, MM; Ferns, GA; Hassanian, SM; Khazaei, M; Parizadeh, MR; Rahmani, F; Ryzhikov, M; Soleimani, A | 1 |
| Asthana, A; Beck, R; Gram, H; Letterio, J; Parameswaran, R; Vicioso, Y; Wong, DP; Zhang, K | 1 |
| Bauer, TM; Clarke, JM; Hwang, S; Jung, SY; Keedy, VL; Kim, SJ; Lee, H; Lee, JI; Park, N | 1 |
| Afshari, AR; Arjmand, MH; Asgharzadeh, F; Avan, A; Binabaj, MM; Fakhraei, M; Ferns, GA; Hassanian, SM; Khazaei, M; Mehraban, S; Naghinezhad, J; Parizadeh, MR; Rahmani, F; Ryzhikov, M; Sayyed-Hosseinian, SH; Soleimani, A | 1 |
| Baek, MJ; Jung, SY; Kang, IM; Kim, DD; Kim, GH; Kim, J; Kim, JM; Lee, JI; Park, JH; Zheng, HM | 1 |
| An, H; Heo, JS; Hong, CP; Hong, E; Kang, JM; Kim, SJ; Lee, S; Ooshima, A; Park, J; Park, JO; Park, S; Park, SH | 1 |
| Rockson, SG | 1 |
| Chung, CH; Ha, KB; Jeong, AR; Kim, DK; Kim, HM; Kukongviriyapan, U; Lee, ES; Lee, EY; Sangartit, W; Shim, S | 1 |
| Cho, I; Choi, J; Park, J; Sheen, Y | 1 |
| Cho, I; Choi, J; Park, J; Sheen, YY | 1 |
1 trial(s) available for triazoles and ew-7197
| Article | Year |
|---|---|
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds; Area Under Curve; Drug Administration Schedule; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms; Receptor, Transforming Growth Factor-beta Type I; Triazoles | 2020 |
19 other study(ies) available for triazoles and ew-7197
| Article | Year |
|---|---|
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
Topics: Administration, Oral; Aniline Compounds; Animals; Antifibrinolytic Agents; Antineoplastic Agents; Biological Availability; Drug Discovery; HEK293 Cells; Humans; Immunotherapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Structure-Activity Relationship; Triazoles | 2014 |
EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
Topics: Aniline Compounds; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Random Allocation; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2014 |
EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.
Topics: Aniline Compounds; Animals; Bleomycin; Blotting, Western; Carbon Tetrachloride; Cell Line; Chromatin Immunoprecipitation; DNA Primers; Fibrosis; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Kidney; Liver; Lung; Mice; Microarray Analysis; Protein Serine-Threonine Kinases; Rats; Reactive Oxygen Species; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; RNA, Small Interfering; Signal Transduction; Smad Proteins; Triazoles | 2015 |
TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Transformed; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Female; Focal Adhesion Protein-Tyrosine Kinases; Hepatic Stellate Cells; Heterografts; Humans; Liver Neoplasms; Mice; Proto-Oncogene Proteins c-akt; Signal Transduction; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Triazoles | 2015 |
Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Disease Models, Animal; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridazines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Transfection; Transforming Growth Factor beta; Triazoles | 2016 |
TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition.
Topics: Aniline Compounds; Animals; Cell Line; Epithelial-Mesenchymal Transition; Hepatic Stellate Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Cirrhosis; Male; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats, Sprague-Dawley; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Triazoles | 2016 |
EW-7197, an activin-like kinase 5 inhibitor, suppresses granulation tissue after stent placement in rat esophagus.
Topics: Actins; Aniline Compounds; Animals; Cadherins; Esophagus; Fibronectins; Granulation Tissue; Male; Nerve Tissue Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Radiography; Rats; Rats, Sprague-Dawley; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Self Expandable Metallic Stents; Smad3 Protein; Transforming Growth Factor beta1; Triazoles | 2017 |
Generation of PDGFRα
Topics: Amides; Aniline Compounds; Animals; Antioxidants; Cell Differentiation; Cell Line; Cells, Cultured; Chromans; Cyclosporine; Enzyme Inhibitors; Humans; Mice; Myoblasts; Myocytes, Cardiac; Pluripotent Stem Cells; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Triazoles | 2017 |
EW-7197 eluting nano-fiber covered self-expandable metallic stent to prevent granulation tissue formation in a canine urethral model.
Topics: Aniline Compounds; Animals; Dogs; Drug-Eluting Stents; Granulation Tissue; Male; Models, Animal; Nanofibers; Triazoles; Urethra | 2018 |
EW-7197, an oral transforming growth factor β type I receptor kinase inhibitor, for preventing peritoneal adhesion formation in a rat model.
Topics: Administration, Oral; Aniline Compounds; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Epithelial-Mesenchymal Transition; Female; Fibrosis; Humans; Peritoneal Diseases; Peritoneum; Postoperative Complications; Protein Kinase Inhibitors; Rats; Rats, Wistar; Receptor, Transforming Growth Factor-beta Type I; Signal Transduction; Surgical Procedures, Operative; Tissue Adhesions; Treatment Outcome; Triazoles | 2018 |
EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents; Antioxidants; Colitis, Ulcerative; Colon; Fibrosis; Inflammation; Male; Mice, Inbred C57BL; Oxidative Stress; Triazoles | 2019 |
Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.
Topics: Adult; Aniline Compounds; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; B-Cell Activation Factor Receptor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Male; Mice; Mice, Inbred NOD; Mice, SCID; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Receptor, Transforming Growth Factor-beta Type I; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Novel oral transforming growth factor-β signaling inhibitor potently inhibits postsurgical adhesion band formation.
Topics: 3T3 Cells; Aniline Compounds; Animals; Apoptosis; Fibroblasts; Gene Expression Regulation; Inflammation; Mice; Oxidative Stress; Random Allocation; Tissue Adhesions; Transforming Growth Factor beta; Triazoles | 2020 |
Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis.
Topics: Administration, Oral; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Bentonite; Biological Availability; Chemistry, Pharmaceutical; Colitis, Ulcerative; Delayed-Action Preparations; Drug Liberation; Freeze Drying; Male; Mice; Mice, Inbred C57BL; Powders; Rats; Rats, Sprague-Dawley; Rodentia; Therapeutic Equivalency; Triazoles | 2020 |
Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; Irinotecan; Leucovorin; Liposomes; Mice, Inbred C57BL; Nanoparticles; Neoplasm Invasiveness; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Transcriptome; Transforming Growth Factor beta; Triazoles; Tumor Stem Cell Assay; Up-Regulation | 2020 |
Inhibition of Fibrosis to Combat Lymphedema.
Topics: Aniline Compounds; Animals; Fibrosis; Lymphedema; Mice; Receptor, Transforming Growth Factor-beta Type I; Transforming Growth Factors; Triazoles | 2020 |
EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation.
Topics: Aniline Compounds; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Mice; Triazoles | 2022 |
Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
Topics: Aniline Compounds; Animals; Breast Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Receptor, Transforming Growth Factor-beta Type I; Transforming Growth Factor beta; Triazoles | 2022 |
Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor.
Topics: Aniline Compounds; Animals; Female; Fibrocystic Breast Disease; Fibronectins; Fibrosis; Humans; Mice; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Oxidative Stress; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; Transforming Growth Factor beta; Transforming Growth Factors; Triazoles | 2022 |